POSSIBILITY OF HELICOBACTER PYLORI ERADICATION THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C

The work shows the possibility of H. pylori (Hp) eradication therapy in patients with chronic hepatitis C (CHC). The aim is to evaluate the efficacy and safety of HP eradication therapy in patients with CHC. The study included 94 patients with chronic hepatitis C, who for various reasons did not receive specific antiviral therapy. Patients were divided into three groups: A – 32 people received standard eradication therapy (SET), which included Rabeprazole 20 mg + Amoxicillin 1000 mg + Clarithromycin 500 mg 2 times a day for 10 days; B – 30 people received CET + probiotic Saccharomyces boulardii orally 1 capsule x 1 g per day for 10 days; C – 32 patients received SET + Saccharomyces boulardii + ursodeoxycholic acid 500 mg/day at night for 1 month. Research results. Analyzing the obtained results, it was found that at the end of SET in all groups of patients there was an improvement in general well-being and a decrease in complaints. The positive effect of the combined use of the probiotic Saccharomyces boulardii and UDCA on the manifestations of asthenovegetative syndrome, characteristic for almost all of patients at the beginning of the observation, was established. After 4 weeks of treatment, manifestations of asthenovegetative syndrome disappeared in 84.4% of patients with group C, which is significantly higher than in groups A and B (65.6% and 68.9%; p <0, 05). Almost at all of patients receiving concomitant probiotic Saccharomyces boulardii and UDCA on the background of SET disappeared the phenomenon of cholestasis, namely subicteric sclera and itchy skin. The percentage of patients with clinical manifestations of cholestasis syndrome in group C at the end of treatment is significantly lower than in groups A and B (6.3%; 12.5% and 10.0%, respectively; p <0.05). Positive changes are registered not only in the well-being of patients, but also in the biochemical parameters of the blood. Addition of probiotic Saccharomyces boulardii and UDCA to SET increases the efficiency of H. pylori eradication by more than 20.0%. The incidence of SET adverse events was significantly lower in patients receiving additional probiotics and UDCA. Conclusion. The effectiveness of eradication therapy in patients with CHC is higher when it includes the probiotic Saccharomyces boulardii and UDCA, which simultaneously reduces the incidence of side effects such as diarrhea, nausea, loss of appetite and flatulence.